AIM ImmunoTech Inc (AIM) has released an update to notify the public and investors about a regulation fd disclosure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AIM has provided a presentation with additional data on its Pancreatic Cancer Early Access Program for the first quarter of 2024, available on its website. The provided information is not considered officially filed for regulatory purposes but may be referenced in future filings if explicitly stated.
For further insights into AIM stock, check out TipRanks’ Stock Analysis page.